AG˹ٷ

STOCK TITAN

Bespoke Extracts, Inc. Announces Financial Results for the Second Quarter ended June 30, 2025

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Bespoke Extracts (OTCQB: BSPK) reported strong Q2 2025 financial results, with revenue reaching $390,553, up 40.4% year-over-year and 48.4% quarter-over-quarter. The company achieved a significant gross margin improvement to 50.6%, representing a 1,250 basis point increase from the previous year.

The quarter marked record production of over 177,000 pre-rolls, with successful market penetration of new product lines Doobskis and Dutch Blunts. The company projects Q3 2025 revenue between $425,000-$450,000, representing a 53-62% year-over-year increase, driven by product line expansion and third-party processing growth.

Bespoke Extracts (OTCQB: BSPK) ha pubblicato solidi risultati finanziari per il secondo trimestre 2025: i ricavi sono saliti a $390,553, in aumento del 40,4% rispetto all'anno precedente e del 48,4% rispetto al trimestre precedente. L'azienda ha migliorato significativamente il margine lordo, che ha raggiunto il 50,6%, pari a un incremento di 1.250 punti base rispetto all'anno precedente.

Il trimestre ha registrato una produzione record di oltre 177.000 pre-roll, con una buona penetrazione di mercato delle nuove linee di prodotto Doobskis e Dutch Blunts. La società prevede ricavi per il terzo trimestre 2025 tra $425,000 e $450,000, un aumento anno su anno del 53-62%, trainato dall'espansione delle linee di prodotto e dalla crescita del processamento per terzi.

Bespoke Extracts (OTCQB: BSPK) informó sólidos resultados financieros del segundo trimestre de 2025, con ingresos que alcanzaron $390,553, un aumento del 40,4% interanual y del 48,4% respecto al trimestre anterior. La compañía logró una notable mejora del margen bruto hasta el 50,6%, equivalente a un incremento de 1.250 puntos básicos respecto al año anterior.

El trimestre marcó una producción récord de más de 177.000 pre-rolls, con una exitosa penetración en el mercado de las nuevas líneas Doobskis y Dutch Blunts. La empresa proyecta ingresos para el tercer trimestre de 2025 entre $425,000 y $450,000, lo que representa un aumento interanual del 53-62%, impulsado por la expansión de líneas de producto y el crecimiento del procesamiento por terceros.

Bespoke Extracts (OTCQB: BSPK)� 2025� 2분기 견조� 실적� 발표했습니다. 매출은 $390,553� 전년 동기 대� 40.4%, 전분� 대� 48.4% 증가했습니다. 회사� 총이익률� 50.6%� 크게 개선했으�, 이는 전년 대� 1,250 베이시스 포인� 상승� 수치입니�.

해당 분기에는 17�7천개 이상� 프리�� 생산하며 사상 최대 실적� 기록했고, 신제� 라인� Doobskis와 Dutch Blunts� 시장 침투에도 성공했습니다. 회사� 2025� 3분기 매출� $425,000~$450,000� 전망하며, 제품 라인 확장� �3� 가� 성장� 힘입� 전년 대� 53~62% 증가� 것으� 예상합니�.

Bespoke Extracts (OTCQB: BSPK) a publié de solides résultats financiers pour le deuxième trimestre 2025, avec un chiffre d'affaires de $390,553, en hausse de 40,4% en glissement annuel et de 48,4% par rapport au trimestre précédent. La société a amélioré significativement sa marge brute, qui est passée à 50,6%, soit un gain de 1 250 points de base par rapport à l'année précédente.

Le trimestre a enregistré une production record de plus de 177 000 pré-rolls, avec une bonne pénétration du marché pour les nouvelles gammes Doobskis et Dutch Blunts. La société prévoit un chiffre d'affaires pour le troisième trimestre 2025 compris entre $425,000 et $450,000, soit une hausse annuelle de 53 à 62%, portée par l'expansion des gammes de produits et la croissance du traitement pour des tiers.

Bespoke Extracts (OTCQB: BSPK) meldete starke Finanzergebnisse für das zweite Quartal 2025: Der Umsatz erreichte $390,553, ein Anstieg von 40,4% gegenüber dem Vorjahr und 48,4% gegenüber dem Vorquartal. Das Unternehmen verbesserte die Bruttomarge deutlich auf 50,6%, was einem Zuwachs von 1.250 Basispunkten gegenüber dem Vorjahr entspricht.

Das Quartal verzeichnete eine Rekordproduktion von über 177.000 Pre-Rolls und eine erfolgreiche Marktdurchdringung der neuen Produktlinien Doobskis und Dutch Blunts. Für das dritte Quartal 2025 prognostiziert das Unternehmen Umsätze zwischen $425.000 und $450.000, ein jährliches Wachstum von 53�62%, angetrieben durch die Erweiterung der Produktlinien und das Wachstum der Drittverarbeitung.

Positive
  • Revenue increased 40.4% year-over-year to $390,553
  • Gross margin expanded 1,250 basis points to 50.6%
  • Record production of 177,995 pre-rolls in Q2 2025
  • Net loss per share improved to $0.02 from $0.03 year-over-year
  • Projected Q3 2025 revenue growth of 53-62% year-over-year
Negative
  • GAAP net loss of $205,106 in Q2 2025
  • Cash position decreased to $1,363 from $60,305 at year-end 2024
  • Total liabilities increased to $2.8M from $2.45M at year-end 2024
  • Stockholders' deficit worsened to -$2.54M from -$2.09M at year-end 2024

AURORA, Colo., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Bespoke Extracts, Inc. (“Bespoke� or the “Company�) (OTCQB: BSPK), today reported its financial results for the quarter ended June 30, 2025. Financial results are reported in accordance with U.S. generally accepted accounting principles (“GAAP�), and all currency is in U.S. dollars.

Michael Feinsod, Chairman and CEO of Bespoke, stated, "Second quarter revenue was $390,553, up 48.4% compared to $263,159 in the first quarter of 2025 and 40.4% compared to $278,163 in the second quarter of 2024. Gross margin of 50.6% increased 1,250 basis points compared to the prior year period. As we continue the Colorado expansion of The Joint Company, we produced and shipped a record number of pre-rolls during the quarter."

Three Months Ended June 30, 2025 Financial Highlights:

  • Revenue of $390,553, an increase of 40.4% over the prior year.
  • Gross profit of $197,499 and gross margin of 50.6%, an increase of 1,250 basis points year-over-year.
  • GAAP net loss of $205,106, compared to $260,895 in the three months ending June 30, 2024
  • Net loss per share of $0.02 per basic and diluted share, compared to a net loss per basic and diluted share of $0.03 in the three months ending June 30, 2024.

Six Months Ended June 30, 2025 Financial Highlights:

  • Revenue of $653,712, an increase of 21.4% over the prior year.
  • Gross profit of $308,278 and gross margin of 47.2%, an increase of 850 basis points year-over-year.
  • GAAP net loss of $465,627, compared to $575,013 in the six months ending June 30, 2024
  • Net loss per share of $0.04 per basic and diluted share, compared to a net loss per basic and diluted share of $0.06 in the six months ending June 30, 2024.

Second Quarter Operational Highlights:

  • Record production during the second quarter of over 177,000 pre-rolls.
  • Continued to achieve cost efficiencies in raw materials, packaging, and labor, increasing gross margins despite increased sampling costs for new product launches and customer acquisition.
  • Continued year-over-year growth of core Fresh Joints product line.
  • DoobskisԻDutch Blunts both achieved meaningful market penetration in the second quarter.
  • Strong growth in our third-party processing business, driven by new client contracts.
For the Three Months Ended
30-Jun-2531-Mar-2530-Jun-24
Revenue$390,553$263,159$278,163
Gross Profit197,499110,779106,117
Gross Profit Margin50.6%42.1%38.1%
Income (Loss) from Operations(161,958)(245,338)(250,895)
Net Income(205,106)(260,521)(260,895)
Shares Outstanding11,153,22011,153,22010,168,220
Net Loss Per Share Out.$(0.02)$(0.02)$(0.03)
Production Data
Joints Produced177,995113,428102,148


For the Six Months Ended
30-Jun-2530-Jun-24
Revenue$653,712$538,591
Gross Profit308,278208,698
Gross Profit Margin47.2%38.7%
Income (Loss) from Operations(407,296)(553,046)
Net Income(465,627)(575,013)
Shares Outstanding11,153,22010,168,220
Net Loss Per Share Out.$(0.04)$(0.06)
Production Data
Joints Produced291,423187,477

Management Commentary

In the second quarter of 2025, our Colorado business, rebranded as The Joint Company, demonstrated robust brand growth and enhanced operational capabilities amid a challenging Colorado cannabis market. Our core Fresh Joints line continued its year-over-year expansion, while new product lines like Doobskis and Dutch Blunts achieved successful market penetration, contributing to a record production of over 177,000 pre-rolls. Bolstered by strong demand in our third-party processing business and ongoing improvements in manufacturing efficiencies—including cost reductions in raw materials, packaging, and labor—we delivered a 40.4% revenue increase to $390,553 and a gross margin expansion to 50.6%. These advancements underscore our ability to scale high-quality pre-roll production and innovate in consumer packaged goods, positioning us for sustained growth and market share gains in the adult-use sector.

Bespoke President Hunter Garth added, “Building on this momentum, the second quarter proved highly productive, marked by strong market share gains in the Colorado pre-roll segment. Looking ahead, we remain confident in our team's capabilities and strategic approach to thrive amid ongoing market challenges. Our ability to achieve record production and market share gains in a competitive and regulated market underscores the strength of The Joint Company brand and operational strategy.”�

Third Quarter 2025 Outlook:

Revenue Growth: Based on preliminary third quarter 2025 sales data, we continue to experience sales growth in our new product lines compared the quarter ended September 30, 2024. The Company projects revenue between $425,000 and $450,000 for the quarter ending September 30, 2025, a 53% to 62% increase over $277,471 in the quarter ended September 30, 2024, driven by continued growth ofFreshJoints, strong demand forDoobskisԻDutch Blunts, and expanded third-party processing services.

Operational Efficiencies: Continued improvements in manufacturing processes are expected to support higher production volumes and consistent product quality.

Gross Margin Improvement: Enhanced production efficiencies and cost management in raw materials, packaging, and labor are projected to drive improved gross margins during the third quarter when compared to the second quarter.

We continue to explore expansion opportunities for The Joint Company in other regulated cannabis markets, such as Massachusetts and New York, to leverage our production expertise. The Company continues to consider opportunities in other business lines.

Bespoke Extracts, Inc
Condensed Consolidated Balance Sheets
June 30,December31,
20252024
Assets
Current assets
Cash$1,363$60,305
Accounts receivable, net101,00757,276
Prepaid expense10,64515,150
Inventory, net41,72132,526
Total current assets154,736165,257
Furniture and equipment, net27,10431,342
License10,00010,000
Right of Use Asset63,198140,489
Deposits12,00012,000
Total assets$267,038$359,088
Liabilities and Stockholders� Equity
Current liabilities
Accounts payable and accrued liabilities$1,344,241$958,276
Note payable15,00020,000
Advances - related party66,87266,872
Operating lease liability59,35373,523
Total current liabilities1,485,4661,118,671
Long-Term liabilities
Notes payable -- secured (Net of discount of $61,427 and $68,649, respectively)298,573241,351
Notes payable169,000169,000
Note payable - related party849,500849,500
Long-Term Operating Lease Liability3,80572,504
Total liabilities2,806,3442,451,026
Commitments and contingencies (Note 8)
Stockholders� Deficit
Preferred stock, par value $0.001, 50,000,000 shares authorized, 0 share issued and outstanding as of June 30, 2025 and December 31,2024, respectively--
Series C Convertible Preferred Stock, $0.001 par value, 1 share designated; 1 share issued and outstanding as of June 30, 2025 and December 31, 2024, respectively, stated value $24,000.--
Common stock, $0.001 par value: 3,000,000,000 authorized; 11,153,220 and 11,153,220 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively11,15111,151
Common stock to issue 6,478 shares--
Additional paid-in capital24,319,28624,301,027
Accumulated deficit(26,869,743)(26,404,116)
Total stockholders� deficit(2,539,306)(2,091,938)
Total liabilities and stockholders� deficit$267,038$359,088

See the accompanying notes to the condensed consolidated financial statements.

Bespoke Extracts, Inc
Condensed Consolidated Statements of Operations

For the three months ended
June 30,
For the Six Months Ended
June 30,
2025202420252024
Sales$390,553$278,163$653,712$538,591
Cost of products sold193,054172,046345,434329,893
Gross Profit197,499106,117308,278208,698
Operating expenses:
Selling, general and administrative expenses337,625325,885650,778673,744
Professional fees21,83230,47564,79688,000
Total operating expenses359,457356,360715,574761,744
Loss from operations(161,958)(250,243)(407,296)(553,046)
Other income / (expenses)
Interest expense(43,148)(10,652)(58,331)(21,967)
Total other (expense) / income(43,148)(10,652)(58,331)(21,967)
Loss before income tax(205,106)(260,895)(465,627)(575,013)
Provision for income tax----
Net Loss$(205,106)$(260,895)$(465,627)$(575,013)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING
Basic and Diluted11,153,22010,168,22011,153,22010,168,220
NET LOSS PER COMMON SHARE OUTSTANDING
Basic and Diluted$(0.02)$(0.03)$(0.04)$(0.06)

Forward-Looking Statements:

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

About Bespoke Extracts, Inc.:

Bespoke Extracts, Inc. is a Nevada corporation operating in the regulated cannabis markets in the United States. Through its wholly-owned subsidiary, Bespoke Extracts Colorado, LLC, the Company operates a marijuana-infused products manufacturing facility in Aurora, Colorado, focusing on delivering high-quality products to licensed dispensaries under its rebranded portfolio, The Joint Company.

Contact:

Bespoke Extracts, Inc.
Email:
Website:

Note: The financial data in this press release is derived from the Company’s unaudited consolidated financial statements included in its Form 10-Q for the quarter ended June 30, 2025, filed with the SEC. Forward-looking revenue projections and expansion plans are based on management’s current expectations and are subject to change.


FAQ

What were Bespoke Extracts (BSPK) key financial results for Q2 2025?

Bespoke reported revenue of $390,553 (up 40.4% YoY), gross margin of 50.6% (up 1,250 bps), and a net loss of $205,106 ($0.02 per share).

How many pre-rolls did Bespoke Extracts produce in Q2 2025?

Bespoke achieved record production of 177,995 pre-rolls in Q2 2025, compared to 102,148 in Q2 2024.

What is Bespoke Extracts (BSPK) revenue guidance for Q3 2025?

The company projects Q3 2025 revenue between $425,000 and $450,000, representing a 53-62% increase over Q3 2024.

How did Bespoke Extracts' gross margin improve in Q2 2025?

Gross margin improved through cost efficiencies in raw materials, packaging, and labor, reaching 50.6%, up 1,250 basis points year-over-year.

What new products contributed to Bespoke Extracts' growth in Q2 2025?

Doobskis and Dutch Blunts achieved meaningful market penetration, while the core Fresh Joints product line continued year-over-year growth.
Bespoke Extracts

OTC:BSPK

BSPK Rankings

BSPK Latest News

BSPK Stock Data

1.90M
8.86M
20.6%
9.1%
Drug Manufacturers - Specialty & Generic
Healthcare
United States
Aurora